Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045266 · ClinicalTrials.gov registry record · Phase 1
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00045266: Completed Phase 1 study, sponsored by Regeneron Pharmaceuticals.
NCT00045266 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045266, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or refractory solid tumors or non-Hodgkin's lymphoma.
Interventions
- BIOLOGICAL ziv-aflibercept
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Phase | Phase 1 |
What the finished NCT00045266 record still lists
NCT00045266 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ziv-aflibercept is the first listed.
NCT00045266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00045266 about?
NCT00045266 is a clinical study titled "VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma". RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or refractory solid tumors or non-Hodgkin's lymphoma.
What is the current status of trial NCT00045266?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-04.
What interventions are being tested in trial NCT00045266?
The interventions under investigation include: ziv-aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00045266?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia